Learn More
To prevent pregnancy loss in women with severe FXIII deficiency, prophylactic replacement therapy with a source of FXIII throughout pregnancy is essential. The aim of this study was to evaluate the bleeding score and rate of successful deliveries in FXIII-deficient pregnant Iranian women receiving regular prophylaxis. Seventeen FXIII-deficient women 18-35(More)
The aim of this study was to evaluate the degree of acceptability of prenatal diagnosis and voluntary termination of pregnancy in case of a fetus affected with beta-thalassemia major (beta-TM) in patients and their parents in Southern Iran. We interviewed 510 parents who had beta-TM children and 254 patients. A questionnaire was used to record information(More)
OBJECTIVE To investigate whether a neonatal screening programme for G6PD deficiency has decreased hospitalization for acute haemolytic attack in the Fars province of southern Iran. METHODS A total of 850 patients registered with G6PD deficiency were included in the study. Variables including age, sex, time and cause of hospitalization, cause of haemolytic(More)
Thrombosis is a common complication in patients with cancer and it is estimated that about 20% of patients with cancer experience venous thromboembolism (VTE). This complication is associated with high rate of morbidity and mortality and is sometimes the first manifestation of an occult cancer. The risk profiles and markers involved in cancerassociated(More)
OBJECTIVES The aim of this study was to determine the association between iron status and febrile seizures in children aged 6 months to 5 years. METHODS This prospective case-control study enrolled 300 children who presented with febrile seizures (case group) and 200 children who presented with a febrile illness without seizures (control group) from March(More)
OBJECTIVES The aim of this study was to investigate the echocardigraphic finding in beta-thalassemia intermedia (TI) and beta-thalassemia major (TM) and to compare this finding together and with healthy control subjects. METHODS Fifty TI, who have been treated with hydroxyurea (HU) for 7 yrs and 51 transfusion dependent TM were compared with 50 age and(More)
Factor XIII (FXIII) is a tetrameric zymogen (FXIII-A (2)B (2)) that is converted into an active transglutaminase (FXIIIa) by thrombin and Ca (2+) in the terminal phase of the clotting cascade. By cross-linking fibrin chains and alpha (2) plasmin inhibitor to fibrin, FXIIIa mechanically stabilizes fibrin and protects it from fibrinolysis. Severe deficiency(More)
The aim of this study was to evaluate the tolerance and adverse effects of hydroxyurea (HU) in thalassemia intermedia (TI) patients who had been treated by HU for a period of 10 years. One hundred forty-three TI patients, including 78 male and 65 female, median age 21 years old (range: 5-37 years old), who were treated by HU were investigated as a case(More)
BACKGROUND The measurements of platelet count and mean platelet volume (MPV) are routinely available nowadays. The aim of this study was to evaluate the platelet count and MPV trend in infectious and inflammatory processes. We also investigated whether these parameters were associated with the known markers of disease activity, erythrocyte sedimentation(More)